Our Technology Platforms

Pharmorage uses two complementary technology platforms, based on small molecules and RNA therapeutics, targeting two levels of the inflammatory signalling pathway:

• The synthetic RNA platform (Pharm-RNA) builds on the identification of a novel class of synthetic RNA/DNA molecules, known as oligonucleotides, that can be used to block the triggers at the source of inflammation. While being pertinent to chronic diseases where immune sensing is dysregulated (e.g. systemic lupus erythematosus), these oligonucleotides can also be designed as adjuvants to improve the production, safety and efficacy of mRNA vaccines.
  
  
• The small molecule / isoflavonoid platform (Pharm-ISO) relies on the development of novel flavonoid compounds modulating the activity of proteins involved at the crossroads of multiple inflammatory signaling pathways. This builds on a wealth of expertise from Noxopharm with isoflavonoids, aiming to target signalling pathways that converge to amplify inflammation. This technology platform is designed to generate treatments for conditions such as motor neurone disease, rheumatoid arthritis, multiple sclerosis, type 1 diabetes mellitus and psoriasis.

Our two platforms are integrated to target two successive levels of innate immune signalling driving inflammation